Immunoassay Systems | IDS 主营:Immunoassay Systems | IDS试剂盒授权代理商
服务电话: 021-52271579

Urine Pre-Clinical CartiLaps® (CTX-II) EIA 品牌Immunoassay Systems | IDS

  • 如果您对该产品感兴趣的话,可以
  • 产品名称:Urine Pre-Clinical CartiLaps® (CTX-II) EIA 品牌Immunoassay Systems | IDS
  • 产品型号:AC-09F1
  • 产品展商:其它品牌
  • 产品文档:无相关文档

品名:Urine Pre-Clinical CartiLaps® (CTX-II) EIA 货号:AC-09F1


Code: AC-09F1

Research Use Only

Clinical Area: Animal Research
Type: Manual
Format: EIA
Number of Tests: 96 (40 samples in duplicate)
Sample Type: Urine
Sample Volume: 10 µL (Pre-diluted (1+3)
Assay Range: 0-100 μg/L

Unique Features

  • Animal Models of Rheumatoid Arthritis and Osteoarthritis
  • Easy, non-invasive quantification of cartilage degradation
  • Strong association to indexes of joint damage, e.g. cartilage erosion
  • Demonstration of Chondroprotective Effect of Drugs
  • Rapid response to chondroprotective drugs (within 1-2 weeks)
  • Early response in CTX-II is highly correlated to histological endpoints3
  • CTX-II can be quantified in relevant cartilage explant culture supernatant human origin and animal models
  • CTX-II is elevated in both RA and OA rat models
  • CTX-II levels are associated with disease activity in RA and OA, primarily indexes of structural damage2
  • Useful for dynamic monitoring of cartilage in multiple species
  • A complete assay panel supporting bone and cartilage research

The Urine Pre-Clinical CartiLaps® (CTX-II) EIA detects degradation products of C-terminal telopeptides of type II collagen (CTX-II) in non-human urine and cell culture supernatant. The test is intended for research use only and not for use in diagnostic procedures.

Disruption of the structural integrity of cartilage is the major histological finding in osteoarthritis and rheumatoid arthritis.

Type II collagen is the major organic constituent of cartilage. Fragments of type II collagen (CTX-II) are being released into circulation and subsequently secreted into urine following degradation of cartilage. In non-human urine, the CTX-II fragments can be quantified by Urine Pre-Clinical CartiLaps® EIA, which in addition is applicable for cell culture supernatants1.

Schaller S et al., In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol. 2005 Oct;3(5):553-80.

Sondergaard BC et al., Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in particular chondrocytes. Osteoarthritis Cartilage. 2006 Aug;14(8):759-68.

Jay GD et al., Prevention of cartilage degeneration and restoration of chondroprotection by lubricin tribosupplementation in the rat following anterior cruciate ligament transection. Arthritis Rheum. 2010 Aug;62(8):2382-91.

Serum Pre-Clinical CartiLaps® (CTX-II) ELISA

Ratlaps™ (CTX-I) EIA